BUZZ-Australia's Prescient Therapeutics hits two-year high on EU nod for cancer therapy
Reuters
Dec 15, 2025
BUZZ-Australia's <a href="https://laohu8.com/S/PTX.AU">Prescient Therapeutics</a> hits two-year high on EU nod for cancer therapy
** Shares of Australia's Prescient TherapeuticsPTX.AX rise as much as 11.2% to A$0.099, their highest since early December 2023
** Clinical-stage oncology firm says that the European Clinical Trials Information System (CTIS) granted authorisation to initiate clinical trial for PTX-100 in patients with relapsed/refractory Cutaneous T-cell Lymphoma
** PTX-100 is a therapy targeting cancer growth pathways
** Co says approval enables activation of trial sites in Italy
** About 5 mln shares change hands, nearly 2.2x 30-day average
** PTX up 94% YTD
(Reporting by Keshav Singh Chundawat in Bengaluru)
((Keshav.singhchundawat@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.